Catalyst Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CATALYST PHARMS, and what generic alternatives to CATALYST PHARMS drugs are available?
CATALYST PHARMS has four approved drugs.
There are fourteen US patents protecting CATALYST PHARMS drugs.
There are one hundred and thirty-four patent family members on CATALYST PHARMS drugs in thirty-four countries and nineteen supplementary protection certificates in fifteen countries.
Summary for Catalyst Pharms
International Patents: | 134 |
US Patents: | 14 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 4 |
Drugs and US Patents for Catalyst Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-005 | Oct 22, 2012 | RX | Yes | No | 6,949,571 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 10,857,161 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 8,334,279 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 11,690,853 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | 6,949,571 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Catalyst Pharms | FIRDAPSE | amifampridine phosphate | TABLET;ORAL | 208078-001 | Nov 28, 2018 | RX | Yes | Yes | 10,793,893 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CATALYST PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | ➤ Subscribe | 2016-10-24 |
International Patents for Catalyst Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20160015408 | ⤷ Try a Trial |
Norway | 20065754 | ⤷ Try a Trial |
China | 1984890 | ⤷ Try a Trial |
New Zealand | 589444 | ⤷ Try a Trial |
European Patent Office | 2053041 | ⤷ Try a Trial |
Israel | 184686 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Catalyst Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1300396 | CA 2012 00052 | Denmark | ⤷ Try a Trial | |
1300396 | 92113 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (FYCOMPA) |
1764361 | C20130021 00081 | Estonia | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEEL;REG NO/DATE: K(2012)5340 LOPLIK 23.07.2012 |
1300396 | C300565 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723 |
1300396 | C01300396/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012 |
1300396 | 2013C/003 | Belgium | ⤷ Try a Trial | PRODUCT NAME: FYCOMPA-PERAMPANEL; AUTHORISATION NUMBER AND DATE: EU/1/12/776/001 20120723 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.